Na Zhang

Dr. Na Zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JWJing Wu
Jing Wu
YYYan-Qiu You
Yan-Qiu You
YMYan-Xiu Ma
Yan-Xiu Ma
YKYan-Hua Kang
Yan-Hua Kang
TWTian Wu
Tian Wu
XPXiao-Ben Pan
Xiao-Ben Pan
Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to suppress acute myeloid leukemia (AML). However, the role of DDX5 remains elusive in APL. Here a DDX5-targeting fully human monoclonal autoantibody named after 2F5 was prepared. It is demonstrated that 2F5 selectively inhibited APL cell proliferation without toxicity to normal neutrophil and tissues. Moreover, 2F5 was confirmed to induce G0/G1 phase arrest in APL cells, and promote APL cell differentiation combined with decreased DDX5 expression and increased reactive oxygen species (ROS) production. Knockdown of DDX5 by siRNA also inhibited proliferation, promoted cell differentiation and enhanced ROS production in APL cells. However, the ROS inhibitor reversed the effects of 2F5 on DDX5 and ROS in APL cells. Thus, we conclude that DDX5-targeting 2F5 inhibits APL cell proliferation, and promotes cell differentiation via induction of ROS. 2F5 showed the therapeutic value of fully human monoclonal autoantibody in APL, which provides a novel and valid approach for treatment of relapse/refractory APL.

1 January 2025 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
HLHangzhou Luo
Hangzhou Luo
YZYong Zheng
Yong Zheng
HPHuaiming Peng
Huaiming Peng
GCGuofan Chen
Guofan Chen
KSKefeng Sun
Kefeng Sun
XZXingwei Zhang
Xingwei Zhang
Background: Cutting balloon (CB) can reduce vascular inflammation and elastic recoil, and these findings have been verified in combination with stent implantation in patients with coronary artery disease (CAD). This study aims to compare the immediate effect of CB with conventional balloon pre‐dilatation before drug‐eluting balloon (DEB) angioplasty for the treatment of CAD. Methods: Patients with CAD, diagnosed by elective coronary angiography and having either de novo lesions or in‐stent restenosis (ISR) were included. All patients were randomly assigned to undergo predilatation with either a CB or a conventional balloon prior to DEB treatment. We assessed the immediate effect and the level of inflammatory factors after the operation between two groups. Results: Eighty‐five patients were enrolled. In the CB group ( n = 42), all patients achieved residual stenosis < 30% (100% procedural success), with no acute complications observed. In the conventional balloon group ( n = 43), 6 patients had residual stenosis ≥ 30% (resulting in an 86.0% procedural success rate), and two acute complications occurred (one type B dissection and one acute branch occlusion), neither requiring bail‐out stenting. Moreover, serum levels of IL‐6, IL‐8, TNF‐α, and CRP at 24 h were significantly higher than those before and immediately after the operation in the two groups. The degrees of increase in concentration of IL‐6, IL‐8, and TNF‐α 24‐h postoperatively were lower in the CB group than those in the conventional balloon group ( P < 0.05). Conclusions: In the treatment of CAD with DEB angioplasty, predilatation with CB was associated with improved immediate procedural success and a reduced inflammatory response compared with conventional balloon predilatation.

5 September 2026 in Ageing Research Reviews
Verified
Journal Article
Closed access
NZNa Zhang
Na Zhang
XFXiaoming Feng
Xiaoming Feng
WZWenchong Zou
Wenchong Zou

Verified
Journal Article
Open access
PDF file
JYJing Yang
Jing Yang
YLYuanheng Li
Yuanheng Li
YFYixuan Feng
Yixuan Feng
YCYixuan Chen
Yixuan Chen
ZLZhongyuan Li
Zhongyuan Li
WZWenchong Zou
Wenchong Zou
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.